Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Average Recommendation of “Moderate Buy” by Analysts

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.

Several equities research analysts recently weighed in on BIOVF shares. HC Wainwright started coverage on Swedish Orphan Biovitrum in a report on Wednesday, May 6th. They issued a “buy” rating for the company. BNP Paribas Exane upgraded Swedish Orphan Biovitrum to an “outperform” rating in a report on Tuesday, February 10th. Danske lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, February 19th. Zacks Research raised shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. Finally, Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th.

Swedish Orphan Biovitrum Price Performance

Shares of BIOVF opened at $47.48 on Wednesday. The firm has a market cap of $16.90 billion, a PE ratio of 158.25 and a beta of 0.36. The firm’s 50 day moving average price is $43.38 and its 200 day moving average price is $39.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.47 and a current ratio of 0.70. Swedish Orphan Biovitrum has a twelve month low of $27.06 and a twelve month high of $47.48.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.07. The firm had revenue of $755.76 million for the quarter, compared to analyst estimates of $749.76 million. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 16.66%. As a group, research analysts expect that Swedish Orphan Biovitrum will post 2.22 EPS for the current fiscal year.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.